MANNII(Manny-eye)

The best microdosing from a special source of ibogaine, supporting mental clarity, well-being and emotional regulation.

What is it?

We believe mannii to represent absolutely the best source of ibogaine, from trees that are over 20 years old, grown by farmers in Central Africa. Tabernanthe mannii (or the round fruited female variant of iboga) is well known to be the superior “wood” with the most beneficial healing qualities and has only been available to the world in any quantity in the last 5 years.

If you are going to microdose anything, ibogaine is the substance you should look into trying, as ibogaine is known to be something of a Swiss army knife for healing the human brain. Ibogaine has recently been receiving a lot of attention, especially in relation to treating addictions and brain injuries. However, we believe that ibogaine is perhaps most beneficial to people in lower doses as an anti-depressant, and for helping to alleviate anxiety and to assist people manage other mental health issues.

View: Mannii Brochure

Why Choose Mannii?

Even in microdoses, ibogaine has been reported to induce a sense of internal guidance or a “voice” that helps users reflect, heal, and reset mentally. While this phenomenon—often described as the “spirit of the plant”—is deeply respected in African traditions, it has yet to be widely acknowledged in Western science.

Scientifically, ibogaine stimulates the production of BDNF (Brain-Derived Neurotrophic Factor) and GDNF (Glial Cell Line-Derived Neurotrophic Factor), essential for neuroplasticity, brain repair, and dopamine regulation. It also helps regulate cortisol levels, calm the Default Mode Network (DMN), and reduce oxidative stress and inflammation in the brain.

How to Take It?

Whilst full flood doses of iboga or ibogaine should generally be experienced under the supervision and guidance of experienced professionals, the MANNII can be taken safely by most people, as long as they are not taking opiates.

Microdosing involves taking very small amounts (typically 1/10th to 1/20th of a therapeutic dose), allowing for subtle yet noticeable improvements in mood, mental clarity, and emotional resilience.
Users often describe a sense of being "guided" or "therapised" by MANNII, supporting daily well-being and long-term mental health.
Effects are generally non-hallucinogenic, and users remain fully functional during daily activities.

As ibogaine is metabolized into noribogaine, its benefits often extend for days or weeks, making it a unique tool for sustained mood support and nervous system healing.

Ibogaine: Mechanisms & Scientific Evidence

A reference table of the key pharmacological mechanisms of ibogaine and noribogaine, with direct links to peer-reviewed studies. Evidence grades: Preclinical = animal/cell data; Clinical = human data; Mechanistic = receptor/molecular binding studies.

Mechanism	Active Compound	Key Studies
BDNF & GDNF Upregulation Increases neurotrophic factors that support dopaminergic neuron survival, drive neuroplasticity, and sustain long-lasting anti-addictive effects via an autocrine GDNF feedback loop in the VTA.	Ibogaine Noribogaine	He et al., 2005 Preclinical GDNF in VTA mediates ethanol reduction — J Neurosci Marton et al., 2019 Preclinical GDNF, BDNF & NGF expression in dopaminergic circuits — Front Pharmacol
SERT & DAT Inhibition Noribogaine noncompetitively inhibits the serotonin transporter (IC₅₀ ~0.18 µM) and competitively blocks the dopamine transporter — producing antidepressant and anti-addictive effects lasting days to weeks from a single dose.	Ibogaine Noribogaine	Bulling et al., 2012 Mechanistic Noncompetitive SERT/DAT inhibition mechanism — J Biol Chem Coleman et al., 2019 Mechanistic Cryo-EM structures of SERT–ibogaine complexes — Nature Baumann et al., 2001 Preclinical In vivo serotonin & dopamine effects in rats — J Pharmacol Exp Ther
NMDA Receptor Antagonism Acts as an open-channel NMDA receptor antagonist, interrupting drug tolerance, blocking excitotoxicity, and disrupting reconsolidation of addiction-related memories — the same mechanism underlying ketamine's rapid antidepressant effects.	Ibogaine	Popik et al., 1994 Mechanistic Competitive inhibitor of [³H]MK-801 binding — Psychopharmacology Popik et al., 1995 Preclinical NMDA antagonist properties; morphine withdrawal attenuation — J Pharmacol Exp Ther Glick et al., 1997 Preclinical Kappa-opioid & NMDA roles in anti-addictive action — Brain Res
Kappa & Mu Opioid Receptor Modulation Noribogaine acts as a G-protein biased kappa-opioid agonist (avoiding dysphoric β-arrestin pathway) and weak mu antagonist — a profile that interrupts opioid withdrawal and tolerance without producing euphoria or dependence.	Noribogaine	Maillet et al., 2015 Mechanistic Noribogaine: G-protein biased κ-opioid agonist — Neuropharmacology Glick et al., 1997 Preclinical Kappa-opioid contribution to anti-addictive mechanism — Brain Res
Sigma-2 Receptor Agonism Ibogaine has higher affinity at sigma-2 receptors than virtually any other known CNS ligand (Ki ~90 nM). Sigma-2 activation drives neuronal repair, remyelination and reduction of neuroinflammation — relevant to MS, TBI and neurodegeneration.	Ibogaine	Bowen et al., 1995 Mechanistic Ibogaine: sigma-2 selective ligand (43-fold over sigma-1) — Eur J Pharmacol Sershen et al., 1996 Preclinical Sigma & NMDA receptor-mediated dopamine release — J Neural Transm
α3β4 Nicotinic Receptor Antagonism Potent noncompetitive blockade of ganglionic α3β4 nicotinic acetylcholine receptors in the medial habenula — a mechanism that reduces self-administration of nicotine, alcohol, opioids and stimulants across substance classes.	Ibogaine	Fryer & Lukas, 1999 Mechanistic Noncompetitive inhibition of ganglionic nAChRs — J Pharmacol Exp Ther Arias et al., 2010 Mechanistic Ibogaine interaction with human α3β4 nAChRs — Int J Biochem Cell Biol Rösner et al., 2023 Preclinical α3β4 inhibitors as SUD treatments — J Med Chem (review)
Remyelination & White Matter Repair Ibogaine upregulates myelination markers CNP and MBP following opioid exposure, and case evidence shows MS lesion shrinkage post-treatment. Converging sigma, kappa-opioid and NMDA actions drive oligodendrocyte repair and reduce excitotoxic demyelination.	Both	Calvey et al., 2024 Preclinical CNP & MBP upregulation after morphine + ibogaine in rats — Front Neurosci Chen et al., 2025 Clinical MS lesion reduction & neural structural changes — Front Immunol
Pharmacochaperone Activity at SERT & DAT Ibogaine and noribogaine are the most potent known pharmacological chaperones for misfolded serotonin and dopamine transporters, rescuing folding-deficient DAT mutations linked to Dopamine Transporter Deficiency Syndrome (infantile Parkinsonism/dystonia).	Noribogaine	Beerepoot et al., 2016 Mechanistic Ibogaine rescues folding-deficient DAT (DTDS mutations) — J Biol Chem Bhat et al., 2021 Mechanistic Tropane ibogaine analog rescues folding-deficient SERT & DAT — ACS Chem Neurosci
VMAT2 Inhibition & "Matrix Pharmacology" Newly identified (2025): ibogaine and noribogaine inhibit vesicular monoamine transporter 2 (VMAT2) at sub-micromolar concentrations at individual synaptic vesicles in mouse brain, alongside a novel target OCT2. This multi-transporter "matrix" may explain the breadth of ibogaine's therapeutic effects.	Both	Hwu et al., 2025 Mechanistic VMAT2, SERT & OCT2 multi-transporter modulation — JACS Hwu et al., 2025 (preprint) Mechanistic Open-access preprint — bioRxiv
Critical Period Reopening & Metaplasticity Ibogaine, alongside psilocybin, MDMA, LSD and ketamine, evokes metaplasticity in the nucleus accumbens to reopen a developmental "critical period" for social reward learning that closes at maturity — potentially the core mechanism underlying all psychedelic-assisted therapy.	Both	Nardou et al., 2023 Preclinical Psychedelics reopen social reward learning critical period — Nature Nardou et al., 2019 Preclinical Oxytocin-dependent critical period reopening with MDMA — Nature (foundational)
TBI, PTSD & Cortical Oscillation Recovery In the landmark Stanford Nature Medicine trial, magnesium-ibogaine produced large reductions in PTSD, depression and anxiety in veterans with TBI. Subsequent neuroimaging found increased theta oscillations (linked to neuroplasticity) and reduced cortical complexity (linked to PTSD improvement).	Ibogaine	Cherian et al., 2024 Clinical Magnesium-ibogaine in veterans with TBI — Nature Medicine Lissemore et al., 2025 Clinical EEG cortical oscillations & complexity after ibogaine — Nature Mental Health
Sustained Serotonergic & Opioid Detox Activity Noribogaine's 28–49 hour half-life provides sustained SERT inhibition and kappa-opioid modulation long after ibogaine is cleared, underpinning durable craving reduction. Observed clinically as reduced opioid withdrawal severity and depression scores lasting weeks to months from a single treatment.	Noribogaine	Mash et al., 2000 Clinical Ibogaine pharmacokinetics & preliminary efficacy — Ann NY Acad Sci Noller et al., 2018 Clinical 12-month follow-up: opioid dependence outcomes — Am J Drug Alcohol Abuse Baumann et al., 2001 Preclinical Comparative neuropharmacology of ibogaine & noribogaine — Alkaloids Chem Biol

Information About Our Shipping Policies

Our attitude to shipping...

What People Are Saying About mannii ?

We now have almost...

How Is Tabernanthe mannii Different From Tabernanthe Iboga?

MANNII is described as...

The mannii tablet sold in France for thirty years

An educational overview of...

9 Things You May Not Know About Ibogaine

Nine things about the...

Most Frequently Asked Questions

What is MANNII?

Microdosing with ibogaine is a way to connect with the plant, not to have a psychoactive experience, but to experience the medicinal and healing qualities of this plant. Even very small amounts, 1 drop or 1mg of ibogaine, we have heard people report remarkable shifts and changes in themselves. We use in our product the round fruited variant of iboga, which is the female variant. Traditionally known as Tabernanthe mannii, when the French and Belgians first began classifying the plant, they saw the Tabernanthe mannii had different shaped leaves, a smaller flower and a different alkaloid profile than iboga. These days most botanists consider mannii to be a variant or subspecies, however, in Central Africa, they consider the round fruited mannii to be the female plant and the eggplant fruited plant to be the male variant. The experience of taking mannii is commonly said to smoother, with a less angular experience and by all reports appears to work on an emotional and soul level, perhaps in a deeper than regular iboga. From the 1930’s to the 1960’s a product was marketed in France containing a Tabernanthe mannii extract called Lambarène, though it was certainly not a microdose, with each pills containing 200mg of root bark extract and people taking from 2-4 pills a day, each pill representing about 15 drop of our mannii.

What are the effects?

Most people will feel a kind of stimulating effect from the drops, and it is best to take the drops in the morning before eating or drinking. Most people will want to have a dosage whereby they feel an expanded sense of awareness, which should be gentle and clarifying in nature and not interrupt daily function, but improve daily functioning. As people continue to take the drops, they may have the ability to observe and understand their problems and issues more easily. Subjectively, people report the mannii drops appear to facilitate a kind of mental and emotional processing, which can be quite strong, and almost physical at times for some, but that experience will generally pass. If people do experience anything like psychoactive effects, it is recommend to reduce the dosage. The effects of the drops are cumulative, so the more you take them, the stronger the effects will be. Some people will not feel anything, we think this is about 10-15% of the population who might not even feel anything much if they drank a whole bottle of the mannii. The taste of the drops is quite sharp, but not unpleasant and the bitter taste stimulates the vagus nerve, resulting in a better absorption of the alkaloids.

Where is the mannii sourced. Is it sustainable?

We obtain our root bark from farmers in Central Africa, not from wild harvested material. Because of the increasing interest in Ibogaine, there are many projects to grow the plants in central Africa, though we could not claim our source is ultimately sustainable. However, due to the very small amount of root bark in one bottle (3 grams), we believe that using the plant in this way, is one of the most impactful and respectful ways to experience this plant medicine.

What are the ingredients of your product.

Our product is made by hand and we only use highest quality ethanol also made by hand only from spring water and sugar which is fermented to create a very high quality spirit. We grind up the root bark and carefully process the root bark in large crystal bowls. There are only two ingredients, the alcohol and the root bark, nothing else is added and there are no impurities in our product as it is very well filtered.

Do you have GMP certification? What about a certificate of analysis?

We are not big enough to justify the expense of GMP certification at this point. Our product is made the way we say it is made and sourced from only the root bark. There are slight variabilities in alkaloids and quantities. We have received quotes of $10,000 to do analysis on our product, so this kind of testing is not as straightforward as people may think.

My friend says Tabernanthe mannii doesn’t exist, and this is only iboga.

We are using the round fruited variant, which used to be classified by the French and Belgians as a different species. In central Africa, they certainly differentiate the female and male variant, and the female round fruited variant is the more highly regarded variant, perhaps because the experience of taking it can be so smooth, whereas the eggplant fruited male variant, can result in a “turbulent” experience at times.

Both Christian Ratsch and Sun Voogelbreinder in their books, which both represent the most extensive encyclopedias of psychoactive plants, communicates of the indigenous differentiation of the round fruited and eggplant fruited variant.

Why do people choose to take the MANNII drops?

Some people are looking for more clarity and resolution of an issue in their lives, which might mean an addiction to nicotine, an obsessive compulsive disorder, a feeling of ennui, perhaps they have had many health challenges or personal challenges in their lives, which they are looking for some assistance with.

Microdosing ibogaine does appear to be very effective, helping people to resolve internal issues and blockages that may be in their way, helping them to affect change and transform their orientation to life.

People can expect to have better dreams, a sense of clarity, better wellbeing and a spaciousness to resolve personal issues and get a better footing in their life.

How to take it?

While larger “flood” doses of iboga or ibogaine are best experienced under supervision of experienced professionals, microdosing the MANNII is an effective way to experience the healing powers of this magic plant, just by taking a few drops of MANNII under the tongue in the morning.

is this the same as the product known as Tabernanthe mannii ?

Yes, it is the same product, just with a slightly different name and different marketing for a different time. We first began to sell Tabernanthe mannii in early 2022.

Where don’t you sell to in the World.

We don’t sell to Israel, France, Sweden, Spain, Finland, Italy, Norway, Belgium, Argentina, Belgium, Brazil, Colombia, France, Finland, Denmark, Hong Kong, Hungary, Iceland, Israel, Italy, Lithuania, Norway, Puerto Rico, Poland, Russia, Romania, Spain, Slovenia, South Africa, Sweden, Switzerland, Taiwan and Turkey due to legal and potential customs issues. We never send to countries where we cannot send to, and will refund you if do not receive your bottles.

I am a former alchoholic, and don’t want to take alcohol, what can I do?

What you can do is to put the drops in a very hot beverage and the alcohol will largely evaporate off within a couple of minutes. But do keep in mind, the amount of alcohol in the drops is actually very little.

As arch Alchemist Steven Buhner says, you can get more alcohol in eating bread, than from alcohol based tinctures.

“The amount of alcohol in tinctures is incredibly tiny. Less than you will get from eating a few pieces of bread (yes, bread does have alcohol in it, enough to produce a breathalyzer reading of 0.05 just by itself). If you are taking 20 drops of a 60 percent alcohol tincture every hour for an acute condition, you will get about one seventeenth of an ounce of alcohol over the course of a day (less than 2ml). If you are taking a general dose (20 drops three times daily), you will be getting about one-thirtieth of an ounce every day. Again, this is less than you will get from eating two slices of bread.”

How best to store the drops?

The drops are packaged in violet blue miron glass bottles, which prevent UV light from entering the bottles. But the tinctures are like any strong alcohol, they will last indefinitely and will not go bad even after many years.

How do you send packages and how long will it take to arrive?

We send packages via airmail, and they take between 7 days and 21 days to arrive depending on where you live in the world. You will receive tracking upon sending. We ensure you receive your package or we will resend your bottle. We never send to anywhere in the world where we have issues with customs.

I’ve heard ibogaine is dangerous and you need to take tests before you take it.

Certainly, if you are taking large doses of ibogaine, of around 1000mg +, then it is wise to do that with a trained professional and have proper medical tests carried out, such as a kidney test and liver test.

However, when taking a microdosing dose, of 10mg (or ten drops) is not going to strain the body in anything like the much bigger doses.

What are the contraindications?

We have found that ibogaine doesn’t contraindicate with pretty much any substance, only opiates and we do not recommend that people combine even microdosing with opiates, even in very small amounts. Wait until you have been off the opiates for at least 48 hours, and then you could take the drops.

Ibogaine appears to be much like caffeine, and so works around anything that people are taking. Even with SSRI’s, there is some scientific research which even suggests that ibogaine will synergise with SSRI’s.

https://pubs.acs.org/doi/10.1021/acsmedchemlett.2c00214